| Schostak, Martin |
PEGASUS, NCT02799706: Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer |
|
|
| Active, not recruiting | 3 | 885 | Europe | Degarelix, approved GnRH agonist, Radiotherapy | European Organisation for Research and Treatment of Cancer - EORTC | Prostate Cancer | 08/23 | 06/26 | | |
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients |
|
|
| Recruiting | 3 | 250 | Europe | Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel | Jena University Hospital, Bayer | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 07/25 | 01/27 | | |
| Completed | N/A | 804 | Europe, Canada, US | Micro-US Targeted Biopsy, MRI Targeted Biopsy | Sunnybrook Health Sciences Centre, Exact Imaging | Prostate Cancer | 09/24 | 11/24 | | |
3DPN, NCT06056505: Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy |
|
|
| Recruiting | N/A | 370 | Europe | partial kidney nephrectomy, DaVinci Robot, Innersight 3D software | University of Leipzig | Kidney Tumor | 03/26 | 09/26 | | |
| Heers, Hendrik |
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients |
|
|
| Recruiting | 3 | 250 | Europe | Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel | Jena University Hospital, Bayer | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 07/25 | 01/27 | | |
